Seven Eight Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-9,450
| Closed | -$392K | – | 727 |
|
|
2024
Q2 | $392K | Buy |
+9,450
| New | +$423K | 0.04% | 563 |
|
|
2024
Q1 | – | Sell |
-134,432
| Closed | -$6.9M | – | 622 |
|
|
2023
Q4 | $6.9M | Buy |
134,432
+80,225
| +148% | +$4.21M | 0.8% | 11 |
|
|
2023
Q3 | $3.15M | Buy |
54,207
+29,263
| +117% | +$1.79M | 0.37% | 59 |
|
|
2023
Q2 | $1.6M | Buy |
24,944
+15,322
| +159% | +$1.03M | 0.26% | 123 |
|
|
2023
Q1 | $667K | Buy |
+9,622
| New | +$679K | 0.14% | 196 |
|
|
2022
Q4 | – | Sell |
-16,833
| Closed | -$1.2M | – | 425 |
|
|
2022
Q3 | $1.2M | Buy |
+16,833
| New | +$1.22M | 0.24% | 122 |
|
|
2021
Q4 | – | Sell |
-177,285
| Closed | -$10.5M | – | 474 |
|
|
2021
Q3 | $10.5M | Buy |
177,285
+146,802
| +482% | +$9.67M | 1.01% | 1 |
|
|
2021
Q2 | $2.02M | Buy |
30,483
+2,783
| +10% | +$181K | 0.28% | 97 |
|
|
2021
Q1 | $1.72M | Hold |
27,700
| – | – | 0.39% | 79 |
|
|
2020
Q4 | $1.72M | Sell |
27,700
-2,000
| -7% | -$123K | 0.39% | 79 |
|
|
2020
Q3 | $1.78M | Buy |
+29,700
| New | +$1.79M | 0.38% | 51 |
|
|
2020
Q2 | – | Sell |
-21,800
| Closed | -$1.22M | – | 340 |
|
|
2020
Q1 | $1.22M | Sell |
21,800
-18,095
| -45% | -$1.11M | 0.31% | 96 |
|
|
2019
Q4 | $2.54M | Buy |
+39,895
| New | +$2.28M | 0.13% | 233 |
|
|
2019
Q2 | – | Sell |
-355,442
| Closed | -$17M | – | 586 |
|
|
2019
Q1 | $17M | Buy |
+355,442
| New | +$17.7M | 0.9% | 24 |
|
|
2018
Q1 | – | Sell |
-104,059
| Closed | -$6.38M | – | 380 |
|
|
2017
Q4 | $6.38M | Buy |
104,059
+46,200
| +80% | +$2.89M | 0.65% | 35 |
|
|
2017
Q3 | $3.69M | Sell |
57,859
-11,400
| -16% | -$666K | 0.45% | 66 |
|
|
2017
Q2 | $3.86M | Buy |
69,259
+16,900
| +32% | +$920K | 0.55% | 48 |
|
|
2017
Q1 | $2.85M | Buy |
52,359
+25,400
| +94% | +$1.39M | 0.55% | 41 |
|
|
2016
Q4 | $1.57M | Sell |
26,959
-30,900
| -53% | -$1.69M | 0.32% | 106 |
|
|
2016
Q3 | $3.12M | Buy |
57,859
+57,500
| +16,017% | +$3.69M | 0.91% | 18 |
|
|
2016
Q2 | $26K | Buy |
+359
| New | +$25.4K | 0.01% | 473 |
|
|
2015
Q4 | – | Sell |
-3,959
| Closed | -$234K | – | 555 |
|
|
2015
Q3 | $234K | Buy |
+3,959
| New | +$251K | 0.2% | 168 |
|
|
2014
Q1 | – | Sell |
-10,759
| Closed | -$572K | – | 292 |
|
|
2013
Q4 | $572K | Buy |
+10,759
| New | +$548K | 0.64% | 28 |
|
Other funds holding BMY
Seven Eight Capital's BMY Position: Q3 2024 in Review
Seven Eight Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 9,450 shares — an estimated $392K sold.
Seven Eight Capital first reported a position in BMY in Q4 2013 and held it in 23 quarters. The position peaked at $17M in Q1 2019. 2,258 funds tracked by Wall St. Rank hold BMY as of Q3 2024.
- Seven Eight Capital reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
- Seven Eight Capital sold 9,450 Bristol-Myers Squibb shares in Q3 2024, an estimated $392K.
- Seven Eight Capital first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 23 quarters.
- Seven Eight Capital's Bristol-Myers Squibb position peaked at $17M in Q1 2019.
- 2,258 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.
Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.